Some analysts are quibbling with the price tag, but no one doubts that Johnson & Johnson will get immediate return from its $30bn bid for Actelion Pharmaceuticals Ltd., a deal transferring a blockbuster respiratory franchise and a pair of promising Phase III assets. Perhaps just as importantly, the Jan. 26 deal includes a spinout of Actelion's R&D engine into a new company, with J&J holding a 16% share and an option to double that stake.
The transaction is an all-cash tender for all outstanding shares in Actelion at $280 per share, contingent upon at least...







